The verdict
Our read at a glance.
Whether a genuinely mild androgen is therefore a safe one, and whether the product sold under the name is the compound at all.
- The signal
- Methenolone has a real clinical history in anaemia and in supportive care, and it retains approvals in a small number of countries, but there is no modern controlled trial programme behind it and none at all in the population using it now. The contemporary indexed literature is largely analytical: metabolite profiling, long-term detection windows and the doping-control chemistry needed to identify it. Its pharmacological profile - a dihydrotestosterone derivative that does not aromatise and has relatively modest anabolic potency - is well characterised and consistent with the mild reputation.
- The unknown
- Whether the mildness translates into a genuinely better risk profile or simply a smaller effect for the same suppression, since the axis shutdown and lipid changes are still present.
- Our read
- The safest-sounding compound in a class where safe is a relative term. It is mild in the sense of having a small effect for a real cost, and the specific practical risk - that the vial contains something cheaper and stronger - is the one least discussed by the people recommending it.
The mechanism
How it works.
Methenolone is a dihydrotestosterone derivative with a 1-methyl group and an added double bond, modifications that make it resistant to metabolic breakdown without requiring 17-alpha alkylation - which is why the injectable form is not hepatotoxic in the way oral 17-alpha-alkylated steroids are. Because it is already 5-alpha reduced it is not a substrate for aromatase, so no oestradiol is produced from it and oestrogenic effects do not occur. Its affinity for the androgen receptor is moderate rather than high, which is the pharmacological basis of the mild reputation: a smaller signal at the receptor produces a smaller anabolic response. What does not scale down proportionally is the feedback suppression, because the brain responds to androgen receptor activation regardless of how much muscle is being built.
Safety & regulatory boundary
The consequential part.
No current FDA-approved product in the United States; a Schedule III controlled substance. Being mild does not mean neutral: it suppresses endogenous testosterone, lowers HDL, and is androgenic enough to cause virilisation in women at sufficient exposure. It is also among the most counterfeited compounds in the illicit market because it is expensive to produce, so the risk of receiving something else entirely is unusually high. Prohibited in sport.
What's next
What we're watching.
Nothing in development; continued analytical surveillance of counterfeit supply is the live issue.
Context
Why this is discussed.
It is the compound most often recommended to women and to people wanting a cautious first cycle, on the grounds that it does not aromatise and is not hepatotoxic in the 17-alpha-alkylated sense.
The evidence base
14 cited references.
Registered trials2
ClinicalTrials.gov · NA · ENROLLING_BY_INVITATION · 2026-03-12
ClinicalTrials.gov · COMPLETED · 2022-05-05
Indexed literature (PubMed)12
Yang Z et al. · Cell · 2025
Zheng J et al. · Drug Test Anal · 2021
Gürses G et al. · J Oral Pathol Med · 2024
Van Hoof N et al. · Vet Res Commun · 2007
Angelis YS et al. · Drug Test Anal · 2023
Fragkaki AG et al. · J Mass Spectrom · 2015
Lockner D · Acta Med Scand · 1979
West HF et al. · Ann Rheum Dis · 1965
Kennedy BJ et al. · Cancer · 1968
Kicman AT et al. · Clin Chem · 1994
FIXSON U · Med Welt · 1962
Ushimaru S et al. · JCEM Case Rep · 2024
Keep reading